PE20000881A1 - Uso de tiazolidindiona como cardioprotector - Google Patents

Uso de tiazolidindiona como cardioprotector

Info

Publication number
PE20000881A1
PE20000881A1 PE1999000726A PE00072699A PE20000881A1 PE 20000881 A1 PE20000881 A1 PE 20000881A1 PE 1999000726 A PE1999000726 A PE 1999000726A PE 00072699 A PE00072699 A PE 00072699A PE 20000881 A1 PE20000881 A1 PE 20000881A1
Authority
PE
Peru
Prior art keywords
diona
benzyl
thiazolidine
methyl
metoxy
Prior art date
Application number
PE1999000726A
Other languages
English (en)
Inventor
Robin Edwin Buckingham
Antoine Michel Alain Bril
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab filed Critical Smithkline Beecham Plc
Publication of PE20000881A1 publication Critical patent/PE20000881A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE AL USO DE UN INTENSIFICADOR DE LA ABSORCION DE GLUCOSA TAL COMO TIAZOLIDINDIONA DE PREFERENCIA 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]-TIAZOLIDINA-2,4-DIONA, (+)-5-[[4-[(3,4-DIHIDRO-6-HIDROXI-2,5,7,8-TETRAMETIL-2H-1-BENZOPIRAN-2-IL)METOXI]FENIL]METIL]-2,4-TIAZOLIDINA (TROGLITAZONA), 5-[4-[(1-METILCICLOHEXIL)METOXI]BENCIL]TIAZOLIDINA-2,4-DIONA (CIGLITAZONA), 5-[4-[2-(5-ETILPIRIDIN-2-IL)ETOXI]-BENCIL]-TIAZOLIDINA-2,4-DIONA (PIOGLITAZONA); 5-[(2-BENCIL-2,3-DIHIDROBENZOPIRAN)-5-ILMETIL]TIAZOLIDINA-2,4-DIONA (ENGLITAZONA) COMO CARDIOPROTECTOR EN UNA PERSONA DIABETICA O PARA REDUCIR O PREVENIR LA APOPTOSIS DE CELULAS DIFERENCIADAS COMO MIOCITOS, CELULAS ß-PANCREATICAS, CELULAS ENDOTELIALES Y CELULAS NEURONALES INDUCIDA POR ATAQUE ISQUEMICO, PRIVACION DE SUERO, ACTIVACION DE CITOQUINAS, REDUCIR LA LESION O MEJORAR LA RECUPERACION FUNCIONAL DEL CORAZON POSTERIOR A LA ISQUEMIA
PE1999000726A 1998-07-21 1999-07-20 Uso de tiazolidindiona como cardioprotector PE20000881A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound

Publications (1)

Publication Number Publication Date
PE20000881A1 true PE20000881A1 (es) 2000-10-07

Family

ID=26314086

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000726A PE20000881A1 (es) 1998-07-21 1999-07-20 Uso de tiazolidindiona como cardioprotector

Country Status (35)

Country Link
EP (2) EP1523980A3 (es)
JP (1) JP2002521325A (es)
KR (1) KR20010079550A (es)
CN (1) CN1167416C (es)
AP (1) AP1416A (es)
AR (1) AR020614A1 (es)
AT (1) ATE318588T1 (es)
AU (1) AU5053599A (es)
BG (1) BG105251A (es)
BR (1) BR9912144A (es)
CA (1) CA2338216A1 (es)
CO (1) CO5060465A1 (es)
CY (1) CY1106078T1 (es)
CZ (1) CZ2001250A3 (es)
DE (1) DE69930125T2 (es)
DK (1) DK1098638T3 (es)
DZ (1) DZ2854A1 (es)
EA (1) EA004772B1 (es)
ES (1) ES2259839T3 (es)
GC (1) GC0000173A (es)
HU (1) HUP0103870A3 (es)
ID (1) ID27850A (es)
IL (1) IL140741A0 (es)
MA (1) MA26662A1 (es)
NO (1) NO20010293L (es)
NZ (1) NZ509175A (es)
OA (1) OA11583A (es)
PE (1) PE20000881A1 (es)
PL (1) PL345663A1 (es)
PT (1) PT1098638E (es)
SI (1) SI1098638T1 (es)
SK (1) SK1022001A3 (es)
TR (1) TR200100208T2 (es)
TW (2) TWI239836B (es)
WO (1) WO2000004889A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
BR0017254A (pt) * 2000-06-16 2004-01-06 Smithkline Beecham Plc Tratamento e prevenção de condições associadas à resistência cardìaca à insulina
CA2452159A1 (en) 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
IL128771A0 (en) * 1996-09-12 2000-01-31 Sankyo Co An agent for enhancing the activity of glutathione reductase containing troglitazone and use thereof
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
CO5060465A1 (es) 2001-07-30
EP1098638B1 (en) 2006-03-01
AP2001002033A0 (en) 2001-03-31
AP1416A (en) 2005-06-13
EP1523980A3 (en) 2009-03-18
KR20010079550A (ko) 2001-08-22
DK1098638T3 (da) 2006-06-19
TWI239836B (en) 2005-09-21
IL140741A0 (en) 2002-02-10
DE69930125T2 (de) 2006-10-05
CY1106078T1 (el) 2011-06-08
NO20010293D0 (no) 2001-01-18
SK1022001A3 (en) 2001-08-06
EP1098638A1 (en) 2001-05-16
TW200307532A (en) 2003-12-16
EP1523980A2 (en) 2005-04-20
CA2338216A1 (en) 2000-02-03
PL345663A1 (en) 2002-01-02
EA004772B1 (ru) 2004-08-26
BR9912144A (pt) 2001-04-03
AU5053599A (en) 2000-02-14
CN1167416C (zh) 2004-09-22
SI1098638T1 (sl) 2006-06-30
JP2002521325A (ja) 2002-07-16
BG105251A (en) 2001-10-31
WO2000004889A1 (en) 2000-02-03
ID27850A (id) 2001-04-26
OA11583A (en) 2004-07-01
TR200100208T2 (tr) 2001-05-21
CN1310619A (zh) 2001-08-29
NZ509175A (en) 2003-10-31
NO20010293L (no) 2001-03-07
HUP0103870A2 (hu) 2002-05-29
DE69930125D1 (de) 2006-04-27
ATE318588T1 (de) 2006-03-15
HUP0103870A3 (en) 2003-06-30
DZ2854A1 (fr) 2003-12-01
GC0000173A (en) 2006-03-29
CZ2001250A3 (cs) 2002-03-13
PT1098638E (pt) 2006-07-31
MA26662A1 (fr) 2004-12-20
ES2259839T3 (es) 2006-10-16
AR020614A1 (es) 2002-05-22
EA200100164A1 (ru) 2001-08-27

Similar Documents

Publication Publication Date Title
HUP0003876A2 (hu) Tiazolidin-dion-származékok alkalmazása polycystás petefészek szindróma és terhességi diabetes kezelésére
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
EP1593379A3 (en) Uses of PPAR-gamma agonists in neutrophil-induced diseases
CO4940420A1 (es) Nuevo metodo de tratamiento
MA29281B1 (fr) Forme posologique orale au rosiglitazone
PE20000881A1 (es) Uso de tiazolidindiona como cardioprotector
CY1106226T1 (el) Μεσυλικο αλας 5-[4-[2-(ν-μεθυλ-ν-(2-πυριδυλ)αμινο)αιθοξυ]βενζυλ]θειαζολιδινο-2,4-διονης
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
CO4940422A1 (es) Novedoso metodo de tratamiento
UY25050A1 (es) Metodo de tratamiento para diabetes mellitus
CO4940489A1 (es) Nuevo metodo de tratamiento cines asociadas a la misma en mamiferos
AP1600A (en) Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
HUP0003397A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione for producing medicament useful in the treatment of polycystic ovary syndrome and gestational diabetes
UY26112A1 (es) Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
NO20075507L (no) Tiazolidindionderivater og deres anvendelse som antidiabetiske midler
NO20076517L (no) Natriumsalter av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksyl]benzyl]tiazolidin-2,4-dion
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
DK1446404T3 (da) Rosiglitazonedisylater og deres anvendelse som antidiabetika
PE20010047A1 (es) Monohidrato de hidrocloruro de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
HUP0301799A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide for treating diabetes mellitus, process for preparation thereof and pharmaceutical composition containing the same
BR0112982A (pt) Sal tartarato de derivado de tiazolidinadiona
RS50130B (sr) Farmaceutska kompozicija 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil) tiazolidin-2,4-diona
WO2003099337A3 (en) Inclusion complexes of rosiglitazone
HUP0003673A2 (hu) Dioxo-tiazolidinek alkalmazása a hyperglykaemia kezelésére

Legal Events

Date Code Title Description
FC Refusal